ROIV - Immunovant stock jumps 9% on positive data for Graves' disease drug
2023-12-21 11:42:39 ET
More on Immunovant, Roivant Sciences, etc.
- 2024 - Liquidia, Burford, And Roivant
- Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena
- Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript
- Immunovant gains after Phase 1 data for autoimmune therapy
- Roivant slides on failed Phase 2 study for lupus drug candidate
For further details see:
Immunovant stock jumps 9% on positive data for Graves' disease drug